DURHAM, N.C., March 30, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer, will participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled “Therapeutic Cancer Vaccines: Stimulating the Immune System,” as well as a second panel discussion starting at 4:30 p.m. ET entitled “Combination Immuno-Oncology Themes.”
The conference is hosted by MaidStone Life Sciences, LLC and William Blair & Company, LLC. For more information, please visit http://www.maidstonels.com/conference.html.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 firstname.lastname@example.org